Chang Xiaoyan, Wang Chenghao, Wang Fei, Zhang Linyou
Department of Thoracic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Department of Radiology, Second Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang, China.
Front Immunol. 2025 Mar 20;16:1555216. doi: 10.3389/fimmu.2025.1555216. eCollection 2025.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and about half of the patients had mutations in the epidermal growth factor receptor (EGFR) gene. Changes in the tumor microenvironment after EGFR mutation are closely related to tumor progression and treatment efficacy.
We searched the Web of Science Core Collection database to select the articles related to tumor microenvironment in non-small cell lung cancer with epidermal growth factor receptor mutation. The countries/regions, institutes, authors, journals, references, and keywords were visualized and analyzed.
227 relevant studies were obtained from WoSCC. These articles came from 102 countries and 1179 institutions. After network analysis, it was found that the intensity of USA cooperation with China was the greatest (LS=13), followed by cooperation with South Korea (LS=3) and with Japan (LS=3). A total of 2267 authors participated the all 227 articles. 112 journals were covered, and published most papers (n=16, 14.3%). A total of 7964 co-cited references are related to TME in NSCLC with EGFR mutation. "EGFR" is the keyword with the highest centrality (C=0.31) and first appeared. The keywords that burst in the last 1 year (2022-2023) are "immunotherapy", "mechanism", "lung neoplasms", "T cells", and "multicenter".
Effective drug treatment of advanced NSCLC with EGFR mutations after failure of first-line chemotherapy is one of the hotspots, in which the efficacy of immune checkpoint inhibitors may be the direction of the current and future studies that need to find a breakthrough.
非小细胞肺癌（NSCLC）是最常见的肺癌类型，约一半的患者表皮生长因子受体（EGFR）基因发生突变。EGFR突变后肿瘤微环境的变化与肿瘤进展和治疗效果密切相关。
我们检索了Web of Science核心合集数据库，以选择与表皮生长因子受体突变的非小细胞肺癌肿瘤微环境相关的文章。对国家/地区、机构、作者、期刊、参考文献和关键词进行可视化分析。
从WoSCC中获得了227项相关研究。这些文章来自102个国家和1179个机构。经过网络分析，发现美国与中国的合作强度最大（LS=13），其次是与韩国（LS=3）和日本（LS=3）。共有2267位作者参与了这227篇文章。涵盖了112种期刊，发表论文最多的期刊有16篇（占14.3%）。共有7964篇共被引参考文献与EGFR突变的NSCLC中的肿瘤微环境相关。“EGFR”是中心性最高（C=0.31）且首次出现的关键词。在过去1年（2022 - 2023年）中出现频次激增的关键词有“免疫疗法”“机制”“肺肿瘤”“T细胞”和“多中心”。
一线化疗失败后对晚期EGFR突变的NSCLC进行有效的药物治疗是热点之一，其中免疫检查点抑制剂的疗效可能是当前及未来需要寻求突破的研究方向。
